Standard therapy for patients with myelodysplastic syndromes

Ali Al-Ameri, Mohamad Cherry, Guillermo Garcia-Manero, Alfonso Quintás-Cardama

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.

Original languageEnglish (US)
Pages (from-to)303-313
Number of pages11
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number4
StatePublished - Aug 2011


  • Azacitidine
  • Decitabine
  • Lenalidomide
  • MDS
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Standard therapy for patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this